Home / Peptide legality / Louisiana
Are peptides legal in Louisiana?
Louisiana treats peptides as restricted: they are lawful only with a valid prescription dispensed through an FDA-compliant 503A compounding pharmacy or a 503B outsourcing facility, and the state Board of Pharmacy has directed pharmacies to stop using unapproved forms of semaglutide.
Legal status overview
Louisiana treats peptides as restricted, meaning they are legal only when a licensed provider prescribes them and they are dispensed through an FDA-compliant 503A compounding pharmacy or a 503B outsourcing facility. The Louisiana Board of Pharmacy has told in-state pharmacies to cease compounding with unapproved forms of semaglutide and told out-of-state pharmacies not to ship it into Louisiana. Louisiana has no separate research-chemical category, so peptides sold for research use only sit outside any state-recognized legal pathway. A 2026 state law, Act 374 (Senate Bill 253), codified at R.S. 37:23.5, bars licensing boards from prohibiting prescribers and pharmacists from providing peptides that are sourced from compliant 503A or 503B facilities.
Key points
- Peptides are lawful in Louisiana only with a valid prescription filled by an FDA-compliant 503A compounding pharmacy or a 503B outsourcing facility; retail sale of peptides labeled research use only has no legal standing. [1]
- The Louisiana Board of Pharmacy directed compounding pharmacies to stop using unapproved forms of semaglutide, though its executive director framed this as enforcing federal limits rather than an outright ban on all semaglutide compounding. [2]
- Louisiana Act 374 of 2026 (Senate Bill 253), codified at R.S. 37:23.5, prevents state licensing boards from prohibiting authorized prescribers from providing peptides sourced from FDA-registered 503A or 503B facilities, with an August 1, 2026 effective date. [1]
- Compounded copies of the GLP-1 class became hard to justify after the FDA declared the semaglutide shortage resolved on February 21, 2025, which ended the routine shortage-based compounding window and prompted multi-state crackdowns. [5]
- BPC-157 and TB-500 are not FDA-approved and have no recognized USP monograph; in April 2026 the FDA removed them from its Category 2 bulk-substances list, which is not the same as authorizing them for compounding. [3]
- Compounded medications are not FDA-approved, are not a generic, and are not evaluated by the FDA for safety, effectiveness, or quality before dispensing. [4]
- The general framework still governs: prescribers must confirm a peptide is not on the FDA prohibited list and must source it through a licensed pharmacy that meets the federal 503A or 503B standards. [1]
Compound-by-compound status
| BPC-157 Restricted | Not FDA-approved and has no USP monograph. Removed from the FDA Category 2 list in April 2026 but not authorized for compounding; lawful in Louisiana only through a valid prescription at a compliant facility, and any compounded product is not FDA-approved, not a generic, and not evaluated by the FDA. |
|---|---|
| GLP-1 class (compounded semaglutide and tirzepatide, e.g. copies of Wegovy® (semaglutide), Ozempic® (semaglutide), Mounjaro® (tirzepatide), Zepbound® (tirzepatide)) Restricted | The Louisiana Board of Pharmacy told pharmacies to cease using unapproved forms of semaglutide after the FDA resolved the shortage. FDA-approved brand products remain prescribable. Compounded GLP-1 medications are not FDA-approved, not a generic, and not evaluated by the FDA. |
| TB-500 (thymosin beta-4 fragment) Restricted | Not FDA-approved and no USP monograph. Same posture as BPC-157: lawful only via valid prescription through a compliant facility, and any compounded form is not FDA-approved, not a generic, and not evaluated by the FDA. |
| Growth hormone / somatropin Restricted | Lawful only as an FDA-approved prescription drug dispensed through a licensed pharmacy. Federal law further limits distribution of human growth hormone to FDA-approved uses, so non-prescription or performance sale is prohibited. |
Frequently asked questions
Can I legally buy peptides over the counter in Louisiana?
No. Louisiana recognizes no research-chemical category, so peptides are lawful only with a valid prescription dispensed through an FDA-compliant 503A compounding pharmacy or a 503B outsourcing facility. This is information, not medical or legal advice.
Is compounded semaglutide still available in Louisiana?
The Louisiana Board of Pharmacy told pharmacies to stop using unapproved forms of semaglutide after the FDA resolved the shortage on February 21, 2025. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA. FDA-approved brand products such as Wegovy® (semaglutide) and Ozempic® (semaglutide) can still be prescribed.
Is BPC-157 legal in Louisiana?
BPC-157 is not FDA-approved and has no USP monograph. It is lawful only through a valid prescription at a compliant pharmacy; the FDA removed it from the Category 2 list in April 2026, which did not authorize it for compounding.
What does Act 374 change for peptides?
Effective August 1, 2026, Act 374 (R.S. 37:23.5) bars Louisiana licensing boards from prohibiting authorized prescribers and pharmacists from providing peptides sourced from FDA-registered 503A or 503B facilities.
Who regulates peptides in Louisiana?
The Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners operate within the federal framework set by the FDA and Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Sources
- Louisiana Peptide Laws & Regulations - PeptideLaws.com (retrieved 2026-09-21)
- Low-cost weight loss drug banned in La. - WWL-TV (retrieved 2026-09-21)
- BPC-157 in 2026: Why Regulatory Limbo Is Not the Same as a Green Light - Holt Law (retrieved 2026-09-21)
- Regulatory Updates on Compounded Peptides - New Drug Loft and VLS Pharmacy (retrieved 2026-09-21)
- Safety worries over copycat versions of Ozempic® and Wegovy® prompt state crackdowns - NBC News (retrieved 2026-09-21)
Last researched: 2026-09-21.